Bezafibrate for primary biliary cholangitis with incomplete UDCA response
Treatments studied
Part of Digestive system clinical trials.
This trial tests if adding bezafibrate (200 mg or 400 mg) to standard UDCA treatment can improve liver function in people with primary biliary cholangitis whose UDCA alone isn't working well enough.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18 to 79 years old
- Diagnosed with primary biliary cholangitis (PBC)
- Been on UDCA for at least 12 months, with a stable dose for the last 3 months
- PBC not well controlled on UDCA alone (based on certain blood test results)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether fenofibrate (a cholesterol medicine) can improve outcomes in people with primary biliary cholangitis (PBC) who already take ursodeoxycholic acid (UDCA) but still have abnormal liver blood tests. It specifically looks at people with “compensated” (stable) cirrhosis—meaning the liver disease is present but not causing severe complications right now.
This trial tests whether adding fenofibrate to ursodeoxycholic acid (UDCA) can improve liver test results in people with primary biliary cholangitis (PBC) who did not respond enough to UDCA alone. It aims to see if the combination works better and is safe for adults with persistent, abnormal liver markers.
This trial tests an experimental drug (CS0159) for people with primary biliary cholangitis (PBC) who either didn't respond well to or couldn't take the standard treatment UDCA. It aims to improve liver function and reduce symptoms.
This trial studies whether bezafibrate, a medication, can help people with primary biliary cholangitis (PBC). You may be considered if your care team is already considering bezafibrate and you meet safety requirements.
This trial tests whether the drug fenofibrate can help people with primary biliary cholangitis (PBC), a chronic liver disease. It is for patients who have already taken fenofibrate in a previous study and want to continue treatment.
This trial tests adding prednisone (a steroid) to ursodeoxycholic acid (a bile acid medicine) for people with primary biliary cholangitis who have a specific type of liver inflammation. The goal is to see if the combination works better at controlling the disease than standard care.
Hear when a new BPC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.